A phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT

摘要: 9001 Background: Three prior phase II studies of Imatinib mesylate (IM) in 62 pts with advanced melanoma reported only 1 response a pt acral melanoma. A proportion melanomas arising from acral, mucosal, and chronic sun damaged (CSD) sites are characterized by KIT mutations (mut) or amplifications (amp) we hypothesized that this subset tumors would be sensitive to IM. We thus designed study IM restricted harboring such alterations KIT. Methods: Pts unresectable CSD whose tumor harbored 4q12 amp FISH mut who had measureable disease RECIST were eligible. received 400 mg BID continually. Response was assessed every cycle (6 wks). Simon 2-stage design employed where initially 16 treated; if ≥ 2 responses observed, total 25 enrolled. If ≥5 seen pts, the considered positive. Results: Of 81 tum...